Arcutis Biotherapeutics (ARQT) Net Margin (2022 - 2026)

Arcutis Biotherapeutics' Net Margin history runs 5 years deep, the most recent figure standing at 10.72% for Q1 2026.

• In Q1 2026, Net Margin rose 2853.0% year-over-year to 10.72%; the TTM figure through Mar 2026 stood at 0.58% (up 6154.0% YoY), while the FY2025 annual figure was 4.3%, up 7979.0% from the prior year.
• Net Margin for Q1 2026 stood at 10.72%, down from 13.41% in the prior quarter.
• The five-year high for Net Margin was 13.41% in Q4 2025, with the low at 14856.41% in Q3 2022.
• The 5-year median for Net Margin is 117.47% (2023), against an average of 1494.41%.
• The sharpest annual moves came in 2023 and 2024: Net Margin soared 1473895 bps in 2023, then surged 2466 bps in 2024.
• Arcutis Biotherapeutics' Net Margin stood at 2432.25% in 2022, then jumped by 94 bps to 150.83% in 2023, then surged by 90 bps to 15.55% in 2024, then surged by 186 bps to 13.41% in 2025, then slumped by 180 bps to 10.72% in 2026.
• Business Quant data shows ARQT's Net Margin at 10.72% in Q1 2026, 13.41% in Q4 2025, and 7.47% in Q3 2025.